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Abstract
Purpose of Review The purpose of the study is to discuss emerging technologies available in the management of type 1 diabetes
in pregnancy.
Recent Findings The latest evidence suggests that continuous glucose monitoring (CGM) should be offered to all women on
intensive insulin therapy in early pregnancy. Studies have additionally demonstrated the ability of CGM to help gain insight into
specific glucose profiles as they relate to glycaemic targets and pregnancy outcomes. Despite new studies comparing insulin
pump therapy to multiple daily injections, its effectiveness in improving glucose and pregnancy outcomes remains unclear.
Sensor-integrated insulin delivery (also called artificial pancreas or closed-loop insulin delivery) in pregnancy has been demon-
strated to improve time in target and performs well despite the changing insulin demands of pregnancy.
Summary Emerging technologies show promise in the management of type 1 diabetes in pregnancy; however, research
must continue to keep up as technology advances. Further research is needed to clarify the role technology can play in
optimising glucose control before and during pregnancy as well as to understand which women are candidates for sensor-
integrated insulin delivery.
Keywords Diabetes inpregnancy .Technology .Continuousglucosemonitoring . Insulinpump .Closed loop .Artificialpancreas
Introduction
Pregnancies in women with type 1 diabetes continue to be at
increased risk of potentially serious complications [1]. The
risk of these complications can be attenuated by tight
glycaemic control preconception and throughout pregnancy
[2, 3]. While tight glycaemic control is central to the manage-
ment of type 1 diabetes in pregnancy, achieving the targets
necessary to reduce pregnancy-related complications remains
challenging. Many physiologic changes throughout pregnan-
cy as well as other unique circumstances such as labour and
delivery and the postpartum period make frequent insulin ad-
justments and close follow-up necessary [4, 5].
Despite specialised interdisciplinary clinics, and advances
in the treatment of women with type 1 diabetes, a large con-
temporary cohort study in the UK found that most women did
not achieve optimal glycaemic control [6••]. More specifical-
ly, only 16 and 40% of women with type 1 diabetes in early
and late pregnancy respectively met guideline-suggested
haemoglobin A1c (HbA1c) targets of less than 48 mmol/mol
(6.5%) [6••]. This nationwide study did note improvement in
some pregnancy outcomes, namely a 2.5-fold reduction in
stillbirths; however, one in two babies still experienced com-
plications related to maternal hyperglycaemia, namely large
for gestational age, preterm delivery and/or admission to neo-
natal intensive care units. It also highlights the substantial
contribution of between clinic variation suggesting much
room for improvement in the way we care for women with
type 1 diabetes before and during pregnancy. The use of tech-
nology in the treatment of women with diabetes may help
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bridge the gap between current and optimal glycaemic control
in pregnancy with the goal of improving outcomes for mother
and infant.
This review will discuss emerging technologies available
in the management of type 1 diabetes in pregnancy and their
effect on glycaemic control and pregnancy outcomes. More
specifically, we will review the use of continuous glucose
monitoring (CGM) technologies, the insulin pump and
sensor-integrated insulin delivery in care of women with type
1 diabetes in pregnancy.
Continuous Glucose Monitoring
CGM uses a sensor inserted subcutaneously to record glucose
concentrations in the interstitial fluid generating almost 300
glucose measurements per day. It communicates the measured
glucoses to a mobile phone, smartwatch or stand-alone receiv-
er device via Bluetooth. The CGM sensor, which is dispos-
able, is typically changed weekly, and the transmitter duration
is approximately 12 months depending on the system. The
accuracy of CGM has improved substantially over the past
5–10 years with some systems now considered accurate
enough to enable pre-meal bolusing without the need for con-
firmation with capillary glucose testing. However, most de-
vices, other than the Flash glucose monitor, still require cali-
bration with capillary glucose testing two to four times a day
[7]. The Flash glucose monitoring system is factory calibrated
and is considered a replacement for capillary glucose testing
rather than a continuous glucose monitoring system as it lacks
hypoglycaemia and hyperglycaemia alerts and alarms and is
not integrated with insulin delivery.
CGM yields rich glucose data that can be used to manage
insulin in real time, examine glycaemic trends, and study glu-
cose metabolism [8]. Outside of pregnancy, CGM has been
shown to improve glucose control in selected populations who
are motivated to wear the device regularly (at least 6 days per
week) [9]. Further evidence suggests that the use of CGM can
also reduce hypoglycaemia [10]. Various studies have
highlighted both benefits and drawbacks of the use of this tool
in women with type 1 diabetes in pregnancy.
CGM and Pregnancy Outcomes
HbA1c is an important tool used to monitor glycaemic control
and assess the maternal-infant level of risk; however, it has
established limitations in pregnancy. Firstly, HbA1c is influ-
enced by physiologic changes in pregnancy such as increased
red cell turnover in early gestation, which is known to change
as pregnancy progresses [11, 12]. Secondly, because HbA1c
levels are physiologically lower in early to mid-pregnancy
(16–20-week gestation), this can give false reassurance to pa-
tients and clinicians. Thirdly, HbA1c represents an average
measure of glycaemic control but does not yield detailed in-
formation on the pattern of daily glycaemic excursions which
is needed to guide therapy adjustments. In contrast, CGM
gives clinicians and researchers detailed information regard-
ing time spent in the recommended target range as well as
patterns of glucose fluctuations that may be used to optimise
diet, lifestyle and insulin adjustments. It also can alert users to
impending hypoglycaemia or hyperglycaemia allowing them
to take earlier corrective action and therefore minimise out-of-
range excursions. The immediate feedback from CGM may
deepen the user’s understanding of what influences their glu-
cose profile and may encourage them to alter diet, activity and
insulin adjustment behaviours.
Four studies, including two recent studies, have examined
the use of CGM in the management of diabetes in pregnancy
(Table 1). Murphy et al. studied 71 women, including 46 with
type 1 diabetes, in an open-label, randomised controlled trial
of patients in the UK [13]. Women randomised to receive
CGM wore it between 8 and 32-week gestation for up to
7 days every 4–6 weeks. Both the women and their healthcare
providers were masked to the CGM information until it was
reviewed at their clinic visit. Authors found that the use of
CGMwas associated with a lower mean HbA1c level between
weeks 32 and 36 (5.8 vs. 6.4%; p = 0.007) and reduced risk of
macrosomia (odds ratio [OR] 0.36 [95% confidence interval
[CI] 0.13 to 0.98]; p = 0.05).
In contrast, Secher et al. did not find evidence of an im-
provement in glycaemic control or pregnancy outcomes in
their larger study of 154 women (123 women with type 1
diabetes and 31 women with type 2 diabetes) [14]. In this
open-label study, womenwere randomised to receive standard
care with or without supplementary real-time CGM. If
randomised to CGM, women were asked to wear the device
for 6 days on five occasions between 8 and 33-week gestation.
The women randomised to CGM reported substantial burdens
such as discomfort with the device, disturbed sleep and tech-
nical challenges, with only 49 women (64%) using it as per
study protocol and only 5 women (7%) wearing CGM for at
least 60% of the time. There was no significant difference in
their primary outcome large for gestational age (45 vs. 34%,
p = 0.19), and at 33 weeks, the HbA1c in each group was
similar (6.1 vs. 6.1%, p = 0.39) [14, 15]. Unfortunately, the
directly observed CGM data was not reported for the control
group in either of these studies. A subsequent Cochrane re-
view of glucose monitoring in diabetes pregnancy concluded
that further high-quality randomised trials evaluating the ma-
ternal, neonatal and psychosocial outcomes were needed [16].
Two contemporary studies “Effectiveness of Continuous
Glucose Monitoring During Diabetic Pregnancy”
(GlucoMOMS trial) and “Continuous Glucose Monitoring in
Women with Type 1 Diabetes in Pregnancy Trial”
(CONCEPTT) examined the use of CGM in pregnancies com-
plicated by diabetes. GlucoMOMS trial was a multicentre
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open-label randomised controlled trial with a concurrent cost-
effectiveness study [17]. Women with type 1 diabetes, type 2
diabetes or gestational diabetes requiring insulin were
randomised to intermittent masked CGM for 5–7 days every
6 weeks vs. standard of care. It included 304 women with
approximately equal numbers with type 1, type 2 and gesta-
tional diabetes, from over 20 sites in the Netherlands. They
found no significant difference in macrosomia between the
two groups (relative risk 0.99 [95% CI 0.76, 1.28]) but did
find less preeclampsia in the CGM group (abstract only) [18].
The inclusion of women with different degrees of glycaemic
disturbance and very different rates of macrosomia, ranging
from just above normal in gestational diabetes to one in two in
type 1 diabetes offspring, makes it difficult to comment defin-
itively on whether there is a role for CGM in any specific type
of diabetes.
CONCEPTT was a multicentre, open-label trial where
women type 1 diabetes preconception or < 14-week gestation
was randomised to capillary glucose monitoring with and
without real-time CGM [19]. In contrast to previous trials of
intermittent retrospective or real-time CGM, in CONCEPTT,
women were recommended to use real-time CGM continu-
ously from randomisation until delivery or 24 weeks after
randomisation in the pre-pregnancy group who did not con-
ceive. It recruited 325 women (110 pre-pregnancy, 215
pregnant) from 31 sites in Canada, the UK, Spain, Italy,
Ireland and the USA making it the largest randomised trial
in type 1 diabetes pregnancy [20••]. The recently reported
results from CONCEPTT found that while pregnant women
randomised to CGM had only slightly lower HbA1c levels
(mean difference − 0.2% [95% CI 0.34, − 0.03%]; p = 0.02),
they spent an additional 100 min per day in the recommended
glucose control range (CGM time in target 70–140 mg/dL
range 68 vs. 61%; p = 0.003) with 72min less hyperglycaemia
(27 vs. 32%; p = 0.03) at 34-week gestation (Fig. 1).
Importantly, the improvements in glucose control were equal
for women using multiple daily injections (MDI) and women
using insulin pumps. There were no substantial between group
differences in patient-reported psychosocial outcomes.
Questionnaires assessing maternal glucose monitoring and
CGM satisfaction indicated overall favourable ratings.
Hypoglycaemia avoidance behaviours decreased over time
in women using CGM, but stayed constant over time in the
control group.
However, the most striking finding was not on maternal
glycaemia but rather on neonatal outcomes, with significant
reductions in the rate of large for gestational age birthweight
(OR 0.51 [95% CI 0.28, 0.90]; p = 0.02), admission to neona-
tal intensive care units (OR 0.48 [95% CI 0.26, 0.86]; p =
0.02) and episodes of neonatal hypoglycaemia requiring intra-
venous dextrose infusion (OR 0.45 [95% CI 0.22, 0.89]; p =
0.02). Furthermore, the infants of mothers randomised to
CGM had a 1-day shorter total length of hospital stay (3.1
vs. 4.0 days; p = 0.009). The numbers needed to treat with
CGM to prevent one complication are six for both neonatal
intensive care admission and large for gestational age and
eight for neonatal hypoglycaemia. The authors therefore con-
clude that CGM should now be offered to all womenwith type
1 diabetes during the first trimester. Further health economic
evaluations are planned to determine whether the additional
costs of CGM are offset by the reductions in neonatal care and
shorter length of hospital stay. The authors did not find con-
vincing evidence to decide whether CGM should be offered to
women before pregnancy. As only a minority of women (15%
in UK nationwide study) achieve target glucose control in
early pregnancy, further research is needed in a larger sample
of pre-pregnant women, preferably over a longer duration
(52 weeks) to determine whether or not there is a role for
CGM in women planning pregnancy.
Using CGM to Gain Insight into Glucose
Pathophysiology
The detailed information provided by CGM is improving our
understanding of various aspects of glucose control and in
some cases deepening our understanding of the complex rela-
tionship between glucose and pregnancy outcomes. Law et al.
examined CGM data from 117 women, including 89 women
with type 1 diabetes, from the first two CGM trials (Murphy
et al., Secher et al.), to understand the complex relationships
between antenatal glycaemic profiles and large for gestational
age infants [21•]. Using a statistical methodology known as
functional data analysis, they demonstrated specific maternal
glycaemic patterns associated with large for gestational age
infants. Lower mean glucose in the first trimester and higher
mean glucose in the second and third trimesters were associ-
ated with large for gestational age. More specifically, the pat-
tern of glucose associated with large for gestational age infants
was lower mid-morning and early evening glucoses in the first
trimester, higher early morning and afternoon glucoses in the
second trimester and higher evening glucoses in the third tri-
mester. Such detailed information regarding glucose profiles
may allow women with diabetes and clinicians to better target
insulin delivery with the aim of optimising time in target range
and decreasing adverse pregnancy outcomes.
In a different study examining the same 117 women from
the same CGM trials (Murphy et al., Secher et al.), Law et al.
used CGM data to calculate estimated average glucoses in
pregnancy [22•]. Authors noted that estimated average glu-
coses, as they relate to HbA1c, differ in pregnancy compared
to estimates outside of pregnancy; a change in HbA1c in preg-
nancy represents a smaller change in estimated average glu-
coses than outside of pregnancy. This study offers patients and
clinicians practical guidance in the management of diabetes in
pregnancy and recommends aiming for an estimated average
glucose of 6.4–6.7 mmol/L in pregnancy.
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These studies describe complexities in glycaemic excur-
sions that could not be understood using HbA1c data alone
and highlight the potential of CGM to understand how glu-
cose profiles relate to pregnancy outcomes and measures as
well as offering clinicians detailed guidance in the care of
women with diabetes in pregnancy.
Insulin Pump Therapy
The physiologic changes throughout pregnancy such as
changes in peripheral glucose disposal, insulin pharmacoki-
netics and decreasing hepatic insulin sensitivity make frequent
insulin adjustments necessary [4, 5, 23]. There are also occur-
rences specific to pregnancy such as antenatal steroid admin-
istration, labour and delivery as well as a rapid increase in
insulin sensitivity immediately postpartum that require further
tailoring of treatment. With these many unique challenges in
pregnancy, the use of an insulin pump, also known as contin-
uous subcutaneous insulin infusion, is an attractive option as it
facilitates subtle changes in insulin dosing. The insulin pump
can be used with capillary glucose monitoring or in conjunc-
tion with CGM. When it is used together with CGM, it is
referred to as sensor-augmented pump therapy.
Pump therapy outside of pregnancy has been shown to
lower HbA1c as well as decrease hypoglycaemia when com-
pared to MDI [24]. However, the recent literature for the use
of pump over MDI in pregnancy is inadequate and largely
reliant on retrospective observational case series with high risk
of bias. The main source of this bias is baseline differences
between pump andMDI users; women on the pump tend to be
older, have a longer duration of diabetes and are more likely to
receive preconception care than women on MDI, making
comparisons between the groups challenging [25–27]. The
earlier literature reported small randomised studies of varying
quality using outdated pumps and MDI from which no con-
clusions can be drawn.
Fig. 1 Continuous glucose monitoring (CGM) measures from
CONCEPTT. a Time in target range 3.5–7.8 mmol/L (70–140 mg/dL).
The home glucose monitoring (HGM) group spent 52% time in target at
baseline (12.5 h/day) rising to 61% (14.6 h/day) at 34 weeks. The CGM
group spent 52% time in target at baseline (12.5 h/day) rising to 68%
(16.3 h/day) at 34-week gestation; p = 0.003 for between group
difference. b Time spent hyperglycaemic > 7.8 mmol/L (140 mg/dL).
The HGM group spent 40% time hyperglycaemic at baseline (9.6 h/
day) reducing to 32% (7.7 h/day) at 34 weeks. The CGM group spent
39% time in target at baseline (9.4 h/day) reducing to 27% (6.5 h/day) at
34-week gestation; p = 0.03 for between group difference. c Time spent
hypoglycaemic < 3.5 mmol/L (70 mg/dL). The HGM group spent 8%
time hyperglycaemic at baseline (1.9 h/day) reducing to 4% (1.0 h/day) at
34 weeks. The CGM group spent 6% time in target at baseline (1.4 h/day)
reducing to 3% (0.7 h/day) at 34-week gestation; p = 0.10 for between
group difference
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Glycaemic Control
Kallas-Koeman et al. performed one of the largest cohort stud-
ies including 133 and 218 pregnancies using pump and MDI
respectively [25]. They found lower HbA1c levels in insulin
pump users than MDI users across all trimesters of pregnancy
in both adjusted and unadjusted analyses. Other studies have
similarly found lower HbA1c associated with insulin pump
use [27–29]. In contrast, a recent Australian study found no
significant difference in the HbA1c between women using
pumps and MDI [26]. However, women using pumps had a
diabetes duration of 20 years compared to 12 years in theMDI
group, highlighting the need for larger scale adequately
powered randomised controlled trials. A recent systematic re-
view noted there were insufficient data to rule out a difference
between the treatment modalities [30].
Safety of Pumps in Pregnancy
While the benefits remain unclear, most studies suggest that
insulin pump use is safe in pregnancy. Pump use does not
appear to increase or decrease severe hypoglycaemia epi-
sodes, although no studies were specifically powered for this
[25–27, 29, 31, 32]. Likewise, for diabetic ketoacidosis, al-
though overall rates are low and even larger sample sizes
would be required to detect between group differences
[25–27, 31].
Pregnancy Outcomes
Overall, studies were underpowered to detect difference in
most pregnancy outcomes [25–27]. Interestingly, two studies
Kallas-Koeman et al. and Neff et al. reported more large for
gestational age infants in mothers using insulin pumps (55.0
vs. 39.2% and 36 vs. 20% respectively), with the latter study
also reporting more caesarean sections in the pump group (80
vs. 54%) [25, 28]. Another reported more neonatal
hypoglycaemia associated with pump use (35 vs. 13%), but
again, there were differences in baseline maternal characteris-
tics of women who were and were not offered pumps [32].
Insulin Pump Use During Labour and Delivery
Tight glycaemic control during labour and delivery is thought
to reduce the risk of neonatal hypoglycaemia [33]. Drever
et al. examined the safety and efficacy of continuing insulin
pump therapy during labour and delivery. In this single-centre
retrospective cohort study of 161 pregnancies, they noted that
pump therapy appeared safe and was associated with better
glycaemic control when compared to women who were
switched from their pumps to intravenous insulin infusions
[34]. Another cohort study of 65 women found that insulin
pump use was safe and performed well (80% of women
maintained glucoses within target) [35]. Taken together, these
data suggest that the continued use of insulin pump therapy in
labour and delivery may be safe and effective in selected pa-
tient populations.
Sensor-Integrated Insulin Delivery
Sensor-integrated insulin delivery is also known as artificial
pancreas, (hybrid) closed loop and automated insulin delivery.
The three components include a CGM, a single or dual hor-
monal pump and a computer algorithm to regulate insulin or
insulin and glucagon delivery. Sensor-integrated insulin deliv-
ery does exactly that; a computer algorithm uses glucose mea-
surements obtained from CGM to determine hormone deliv-
ery over time via subcutaneous infusion pump(s). There are
many types of sensor-integrated insulin delivery systems. The
first commercially available sensor-integrated insulin delivery
system, the Medtronic Minimed 670G (Dublin, Ireland), is
now available for use in the USA.
A recent meta-analysis of 24 randomised controlled trials
(among 585 participants) outside of pregnancy demonstrated
that sensor-integrated insulin delivery improved time in range
(approximately 70–180 mg/dL) by almost 3 h a day compared
to stand-alone pump therapy [36•]. It was also associated with
almost 50% less time spent hypoglycaemic (from approxi-
mately 5 to 2.5%).
The first trial of sensor-integrated insulin delivery in preg-
nancy included 16women with type 1 diabetes [37••].Women
were randomised to a 4-week period of overnight sensor-
integrated insulin delivery, compared to sensor-augmented in-
sulin delivery (insulin pump therapy with the use of real-time
CGM). Following this, there was a continuation phase of day-
and-night sensor-integrated insulin delivery to assess longer
term feasibility. Sensor-integrated insulin delivery improved
time in target by 15% without increasing hypoglycaemia.
Fourteen of the 16 women chose to continue the sensor-
integrated insulin delivery system throughout pregnancy.
The system continued to perform well as pregnancy
progressed, throughout antenatal steroid administration, la-
bour and delivery, hospitalisations and up to 48 h postpartum
when it was discontinued.
Farrington et al. highlighted both the advantages and con-
cerns expressed by the women who used the sensor-integrated
insulin delivery system in pregnancy [37••, 38•]. While wom-
en experienced feelings of improved control, excitement to-
ward the technology and empowerment regarding their diabe-
tes, they also noted concerns about the cumbersome nature of
the devices, problems with technical glitches and alarms and
concern that with the help of sensor-integrated insulin deliv-
ery, they may lose awareness and knowledge regarding diabe-
tes. This study highlights important areas for researchers and
clinicians to focus on as the technology becomes more widely
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available. It also highlights the importance of considering the
burdens noted by women using this technology as the tech-
nology and evidence advance.
While a commercial hybrid closed loop is available in the
USA (the Medtronic Minimed 670G (Dublin, Ireland)), it has
challenges in its potential use in pregnancy. It has only been
examined in a non-randomised fashion in a non-pregnant pop-
ulation [39]. This study demonstrated a mean time in the target
range of 71–180 mg/dL of only 72.2% (SD 8.8); further studies
would be needed to see if this closed-loop system can achieve
the tight glycaemic targets required to reduce pregnancy com-
plications. Furthermore, glucose targets are pre-set in this com-
mercial device and cannot be lowered by the user or clinician
making its use in pregnancy inadequate at present. For now,
sensor-integrated insulin delivery has shown promise as a tool
in the management of type 1 diabetes in pregnancy. However,
this technology must now be studied in larger trials in pregnan-
cy including more diverse populations and settings.
Conclusions
Emerging technologies in the treatment of type 1 diabetes in
pregnancy including CGM, insulin pumps and most recently
sensor-integrated insulin delivery show promise in the man-
agement of this challenging condition. However, barriers such
as cost and the education necessary for each technology must
also be considered. The speed of the progress of these tech-
nologies offers improvements in accuracy, performance and
device burdens associated with their use but also makes it
challenging for clinicians to keep up with this ever-changing
landscape. An understanding of the current literature is essen-
tial, as previously done studies with older devices may not be
generalisable to the latest technologies. It also challenges cli-
nicians and women with diabetes to understand and expertly
use the various new systems.
Manywomenwith type 1 diabetes put in a tremendous effort
in managing their diabetes and may face feelings of concern
when their glucose is out of target, pressure to achieve optimal
glycaemic control, concern regarding previous pregnancy com-
plications and a desire for a “normal” pregnancy [40, 41].
Despite this, many are unable to achieve guideline-
recommended glycaemic targets [6••]. We must find treatments
for diabetes that are effective but not all consuming.
Technology in the treatment of diabetes may allow us to do
so, but there is still much work to be done. It is essential that
research continues to keep a fast pace as technology advances
and that the perspective of womenwith type 1 diabetes be taken
into consideration as we move forward. The latest evidence
suggests that CGM should be offered to all women on intensive
insulin therapy. Future research is needed to optimise glucose
control before pregnancy and to understand which women are
candidates for sensor-integrated insulin delivery.
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